Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhou Feng
Observed name:
Feng Zhou
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-2103-1741
Observed ORCID:
0000-0002-2103-1741
OpenAlex ID:
A5003317478
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
2023
·
Preeti Narayan
, Asma Dilawari
, et al.
·
Journal of Clinical Oncology
·
59
Inhaled Fluticasone Propionate by Diskus in the Treatment of Asthma
2003
·
Mary E. Purucker
, Curtis J. Rosebraugh
, et al.
·
CHEST Journal
·
36
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
2023
·
Jennifer J. Gao
, Christy L. Osgood
, et al.
·
Clinical Cancer Research
·
13
PDF
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
2023
·
Elaine Chang
, Noah M. Hahn
, et al.
·
Bladder Cancer
·
9
PDF
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.
2024
·
Felice Yang
, Catherine C. Lerro
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration.
2023
·
Felice Yang
, Yue Huang
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Trend changes of national zolpidem users and exposure cases after FDA drug safety communications
2021
·
Esther H. Zhou
, Zhou Feng
, et al.
·
Pharmacoepidemiology and Drug Safety
·
2
Show more works
View as search
Works count:
7
Citation count:
127
H-index:
4
I10-index:
3
Year
Topic
Type